Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic Article

Full Text via DOI: 10.1086/526772 PMID: 18199045 Web of Science: 000252617600017

Cited authors

  • Billeter, Marianne; Zervos, Marcus J.; Chen, Anne Y.; Dalovisio, Joseph R.; Kurukularatne, Changa


  • The increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing. Clinical studies comparing linezolid with 2 doses of dalbavancin have shown comparable efficacy for the treatment of skin and soft-tissue infection. Dalbavancin has also proven to be effective for therapy of catheter-related bloodstream infections. It has an excellent safety profile in studies to date. Dalbavancin will likely have a significant role in outpatient intravenous therapy for patients with potentially serious drug-resistant gram-positive coccal infections.

Publication date

  • 2008

Published in

International Standard Serial Number (ISSN)

  • 1058-4838

Start page

  • 577

End page

  • 583


  • 46


  • 4